Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin S Hirsch

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384Rajesh T Gandhi, John Spritzler, Ellen Chan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2003
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionMartin S Hirsch, Roy T Steigbigel, Scholomo Staszewski, et al.
AIDS (London, England)|April 18, 2003
Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infectionCecile L Tremblay, Jennifer L Hicks, Lorraine Sutton, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith, Gregory K Robbins, Robert W Shafer, et al.
The Journal of Infectious Diseases|September 30, 2015
Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic PotentialGregory M Frank, Amesh Adalja, Alan Barbour, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2008
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch, Huldrych F Günthard, Jonathan M Schapiro, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|October 28, 2009
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch, Huldrych F Günthard, Jonathan M Schapiro, et al.
Antiviral Research|October 23, 2004
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitisMichael J Borucki, John Spritzler, David M Asmuth, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384Rajesh T Gandhi, John Spritzler, Ellen Chan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2003
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionMartin S Hirsch, Roy T Steigbigel, Scholomo Staszewski, et al.
AIDS (London, England)|April 18, 2003
Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infectionCecile L Tremblay, Jennifer L Hicks, Lorraine Sutton, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith, Gregory K Robbins, Robert W Shafer, et al.
The Journal of Infectious Diseases|September 30, 2015
Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic PotentialGregory M Frank, Amesh Adalja, Alan Barbour, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2008
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch, Huldrych F Günthard, Jonathan M Schapiro, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|October 28, 2009
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch, Huldrych F Günthard, Jonathan M Schapiro, et al.
Antiviral Research|October 23, 2004
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitisMichael J Borucki, John Spritzler, David M Asmuth, et al.
Pageof 5